1. <18 years of age 2. Patient is known to be pregnant 3. Known active malignancy that required treatment in the last year 4. WHO (2019) Class III, IV or V pulmonary hypertension 5. Venous thromboembolism currently receiving anti-coagulation or within the past 3 months 6. Currently receiving extracorporeal life support 7. Severe chronic liver disease (Child-Pugh score >12) 8. “Do Not Attempt Resuscitation” order in place 9. Treatment withdrawal imminent within 24 hours 10. BMI > 45 kg/m2. 11. Received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. 12. Known positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus, Hepatitis C virus or any other infection which the opinion of the Investigator is likely to impact on the ability of the patient to participate in the study. 13. Known sensitivity to DMSO or any other component of the study treatments.

1. <18 years of age 2. Patient is known to be pregnant 3. Known active malignancy that required treatment in the last year 4. WHO (2019) Class III, IV or V pulmonary hypertension 5. Venous thromboembolism currently receiving anti-coagulation or within the past 3 months 6. Currently receiving extracorporeal life support 7. Severe chronic liver disease (Child-Pugh score >12) 8. “Do Not Attempt Resuscitation” order in place 9. Treatment withdrawal imminent within 24 hours 10. BMI > 45 kg/m2. 11. Received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. 12. Known positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus, Hepatitis C virus or any other infection which the opinion of the Investigator is likely to impact on the ability of the patient to participate in the study. 13. Known sensitivity to DMSO or any other component of the study treatments.

1. <18 years of age 2. Patient is known to be pregnant 3. Known active malignancy that required treatment in the last year 4. WHO Class III or IV pulmonary hypertension 5. Venous thromboembolism currently receiving anti-coagulation or within the past 3 months 6. Currently receiving extracorporeal life support 7. Severe chronic liver disease (Child-Pugh score >12) 8. “Do Not Attempt Resuscitation” order in place 9. Treatment withdrawal imminent within 24 hours 10. BMI > 45 kg/m2. 11. Received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. 12. Known positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus, Hepatitis C virus or any other infection which the opinion of the Investigator is likely to impact on the ability of the patient to participate in the study. 13. Known sensitivity to DMSO or any other component of the study treatments.

1. <18 years of age 2. Patient is known to be pregnant 3. Known active malignancy that required treatment in the last year 4. WHO Class III or IV pulmonary hypertension 5. Venous thromboembolism currently receiving anti-coagulation or within the past 3 months 6. Currently receiving extracorporeal life support 7. Severe chronic liver disease (Child-Pugh score >12) 8. “Do Not Attempt Resuscitation” order in place 9. Treatment withdrawal imminent within 24 hours 10. BMI > 45 kg/m2. 11. Received any investigational research agent within 60 days or within five half-lives of the last treatment (if the half-life of the investigational agent is known to be longer than 12 days) prior to the planned administration of study treatment. 12. Known positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus, Hepatitis C virus or any other infection which the opinion of the Investigator is likely to impact on the ability of the patient to participate in the study. 13. Known sensitivity to DMSO or any other component of the study treatments.